Dry Eye Syndrome Treatment Market Size, Share, Growth Analysis, By Product(Artificial tears, anti-inflammatory drugs, punctal plugs, and others), By Distribution channel(Hospitals, clinics, retail pharmacies, and e-commerce platforms), By Region - Industry Forecast 2024-2031

Dry Eye Syndrome Treatment Market size was valued at USD 6.61 billion in 2022 and is poised to grow from USD 7.07 billion in 2023 to USD 12.15 billion by 2031, at a CAGR of 7.0% during the forecast period (2024-2031).

The global dry eye syndrome treatment market is characterized by intense competition among key players striving to gain a competitive edge. Established pharmaceutical companies and innovative biotech firms are engaged in continuous research and development to introduce advanced therapies and novel treatment options. Additionally, strategic collaborations, mergers, and acquisitions are prevalent in the market to expand product portfolios and enhance global market presence. Factors such as rising awareness of dry eye syndrome, an aging population, and technological advancements contribute to the market's growth, fostering a highly competitive landscape focused on addressing patient needs effectively. 'Allergan, Inc. (Now AbbVie Inc.) - USA', 'Novartis AG - Switzerland', 'Santen Pharmaceutical Co., Ltd. - Japan', 'Otsuka Holdings Co., Ltd. - Japan', 'Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) - Canada', 'Johnson & Johnson - USA', 'Shire (now part of Takeda Pharmaceutical Company Limited) - Ireland', 'Alcon (formerly part of Novartis) - Switzerland', 'Sun Pharmaceutical Industries Ltd. - India', 'Aerie Pharmaceuticals, Inc. - USA', 'Nicox S.A. - France', 'Akorn Pharmaceuticals - USA', 'Aurohealth - USA', 'Kala Pharmaceuticals, Inc. - USA', 'Auven Therapeutics (Now part of Sun Pharmaceutical Industries Ltd.) - USA', 'Bridge Pharma, Inc. - USA', 'Hanall Pharmaceutical Co., Ltd. - South Korea', 'Horus Pharma - France', 'Novagali Pharma S.A. (Now part of Santen Pharmaceutical Co., Ltd.) - France', 'Mitotech S.A. – Luxembourg'

The growing prevalence of dry eye syndrome (DES) worldwide is a significant driver propelling the growth of the global dry eye syndrome treatment market. Factors such as increasing screen time due to digitalization, aging population, environmental pollution, and lifestyle changes have contributed to a higher incidence of DES. As a result, there is a rising demand for effective and innovative treatment options, including artificial tears, anti-inflammatory medications, and punctal plugs, driving the market's expansion.

There was a growing preference for preservative-free eye drops and artificial tears due to increased awareness about potential side effects of preservatives.

North America dominated the market due to high awareness, advanced healthcare infrastructure, and a large patient pool. Europe followed closely, driven by an aging population and increasing prevalence of dry eye cases.